These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35132875)

  • 1. ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.
    Capodanno D; Angiolillo DJ; Lennon RJ; Goodman SG; Kim SW; O'Cochlain F; So DY; Sweeney J; Rihal CS; Farkouh M; Pereira NL
    J Am Heart Assoc; 2022 Feb; 11(4):e024156. PubMed ID: 35132875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
    JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.
    Madan M; Abbott JD; Lennon R; So DYF; MacDougall AM; McLaughlin MA; Murthy V; Saw J; Rihal C; Farkouh ME; Pereira NL; Goodman SG;
    J Am Heart Assoc; 2022 Jun; 11(12):e024709. PubMed ID: 35699175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y
    Mathew RO; Sidhu MS; Rihal CS; Lennon R; El-Hajjar M; Yager N; Lyubarova R; Abdul-Nour K; Weitz S; O'Cochlain DF; Murthy V; Levisay J; Marzo K; Graham J; Dzavik V; So D; Goodman S; Rosenberg YD; Pereira N; Farkouh ME
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):447-457. PubMed ID: 36445624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.
    Angiolillo DJ; Capodanno D; Danchin N; Simon T; Bergmeijer TO; Ten Berg JM; Sibbing D; Price MJ
    JACC Cardiovasc Interv; 2020 Mar; 13(5):606-617. PubMed ID: 32139218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
    Thomas CD; Franchi F; Keeley EC; Rossi JS; Winget M; David Anderson R; Dempsey AL; Gong Y; Gower MN; Kerensky RA; Kulick N; Malave JG; McDonough CW; Mulrenin IR; Starostik P; Beitelshees AL; Johnson JA; Stouffer GA; Winterstein AG; Angiolillo DJ; Lee CR; Cavallari LH
    Clin Pharmacol Ther; 2022 Jul; 112(1):146-155. PubMed ID: 35429163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-Guided P2Y
    Parcha V; Heindl BF; Li P; Kalra R; Limdi NA; Pereira NL; Arora G; Arora P
    Circ Genom Precis Med; 2021 Dec; 14(6):e003353. PubMed ID: 34670396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Impact of Clinical Factors for Predicting High Platelet Reactivity on Clinical Outcomes in Acute Myocardial Infarction Patients Treated With Clopidogrel and Prasugrel.
    Goto H; Saito Y; Matsumoto T; Sato T; Yamashita D; Suzuki S; Wakabayashi S; Kitahara H; Sano K; Kobayashi Y
    J Atheroscler Thromb; 2023 Dec; 30(12):1791-1802. PubMed ID: 37316266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic-Guided Oral P2Y
    Ingraham BS; Farkouh ME; Lennon RJ; So D; Goodman SG; Geller N; Bae JH; Jeong MH; Baudhuin LM; Mathew V; Bell MR; Lerman A; Fu YP; Hasan A; Iturriaga E; Tanguay JF; Welsh RC; Rosenberg Y; Bailey K; Rihal C; Pereira NL
    JACC Cardiovasc Interv; 2023 Apr; 16(7):816-825. PubMed ID: 37045502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study.
    Fanaroff AC; Kaltenbach LA; Peterson ED; Akhter MW; Effron MB; Henry TD; Wang TY
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29437596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Clopidogrel vs Alternative P2Y
    Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Ortega-Paz L; Gong Y; Kerensky RA; Kulick N; McDonough CW; Nguyen AB; Wang Y; Winget M; Yang WE; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Lee CR; Cavallari LH
    J Am Coll Cardiol; 2024 Apr; 83(15):1370-1381. PubMed ID: 38599713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial.
    Dai L; Xu J; Yan H; Chen Z; Pan Y; Meng X; Li H; Wang Y
    Stroke; 2022 Feb; 53(2):465-472. PubMed ID: 34666508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre trial (NCT01930773).
    Kołtowski Ł; Aradi D; Huczek Z; Tomaniak M; Sibbing D; Filipiak KJ; Kochman J; Balsam P; Opolski G
    Kardiol Pol; 2016; 74(4):372-9. PubMed ID: 26365936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study.
    Lattuca B; Silvain J; Yan Y; Pouillot C; Cuisset T; Cayla G; Henry P; Diallo A; Elhadad S; Rangé G; Lhermusier T; Boueri Z; Motreff P; Carrié D; Vicaut E; Montalescot G; Collet JP
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e007749. PubMed ID: 31694410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
    Bossard M; Granger CB; Tanguay JF; Montalescot G; Faxon DP; Jolly SS; Widimsky P; Niemela K; Steg PG; Natarajan MK; Gao P; Fox KAA; Yusuf S; Mehta SR
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29101117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
    JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
    Gross L; Trenk D; Jacobshagen C; Krieg A; Gawaz M; Massberg S; Baylacher M; Aradi D; Stimpfle F; Hromek J; Vogelgesang A; Hadamitzky M; Sibbing D; Geisler T
    Thromb Haemost; 2018 Sep; 118(9):1656-1667. PubMed ID: 30103241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
    Palmerini T; Calabrò P; Piscione F; De Servi S; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Barozzi C; Tomasi L; Della Riva D; Mariani A; Taglieri N; Reggiani LB; Bianchi R; De Rosa R; Mariani M; Podda G; Généreux P; Stone GW; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1117-27. PubMed ID: 25240538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
    Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
    Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.